Chen H, Hsu R, Fang C, Desai A, Lee N, Hwu W
Front Immunol. 2024; 15:1336599.
PMID: 38715621
PMC: 11074348.
DOI: 10.3389/fimmu.2024.1336599.
Inci A, Ezgu F, Tumer L
Paediatr Drugs. 2024; 26(3):287-308.
PMID: 38664313
PMC: 11074017.
DOI: 10.1007/s40272-024-00627-9.
Pfrimmer C, Smitka M, Muschol N, Husain R, Huemer M, Hennermann J
J Neuromuscul Dis. 2023; 11(1):167-177.
PMID: 38043017
PMC: 10789365.
DOI: 10.3233/JND-230164.
Kistner A, Chichester J, Wang L, Calcedo R, Greig J, Cardwell L
Gene Ther. 2023; 31(3-4):128-143.
PMID: 37833563
PMC: 10940161.
DOI: 10.1038/s41434-023-00423-z.
Ditters I, van Kooten H, van der Beek N, van der Ploeg A, Huidekoper H, van den Hout J
Biomolecules. 2023; 13(9).
PMID: 37759814
PMC: 10526476.
DOI: 10.3390/biom13091414.
Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives.
El Haddad L, Khan M, Soufny R, Mummy D, Driehuys B, Mansour W
Ther Clin Risk Manag. 2023; 19:713-729.
PMID: 37680303
PMC: 10480292.
DOI: 10.2147/TCRM.S362871.
Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
Ertoy Karagol H, Inci A, Polat Terece S, Kilic A, Demir F, Yapar D
Int Arch Allergy Immunol. 2023; 184(4):370-375.
PMID: 36623499
PMC: 10137310.
DOI: 10.1159/000528343.
Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.
Rana J, Munoz M, Biswas M
Cell Immunol. 2022; 382:104641.
PMID: 36402002
PMC: 9730862.
DOI: 10.1016/j.cellimm.2022.104641.
The Clinical Management of Pompe Disease: A Pediatric Perspective.
Marques J
Children (Basel). 2022; 9(9).
PMID: 36138713
PMC: 9497581.
DOI: 10.3390/children9091404.
A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease.
Zhu D, Zhu J, Qiu W, Wang B, Liu L, Yu X
Front Pharmacol. 2022; 13:903488.
PMID: 35833019
PMC: 9271607.
DOI: 10.3389/fphar.2022.903488.
Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease.
Liang Q, Vlaar E, Catalano F, Pijnenburg J, Stok M, van Helsdingen Y
Mol Ther Methods Clin Dev. 2022; 25:520-532.
PMID: 35662813
PMC: 9127119.
DOI: 10.1016/j.omtm.2022.04.016.
What's new and what's next for gene therapy in Pompe disease?.
Roger A, Sethi R, Huston M, Scarrow E, Bao-Dai J, Lai E
Expert Opin Biol Ther. 2022; 22(9):1117-1135.
PMID: 35428407
PMC: 10084869.
DOI: 10.1080/14712598.2022.2067476.
To detect potential pathways and target genes in infantile Pompe patients using computational analysis.
Karadag Gurel A, Gurel S
Bioimpacts. 2022; 12(2):89-105.
PMID: 35411297
PMC: 8905584.
DOI: 10.34172/bi.2022.23467.
Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel.
Gragnaniello V, Deodato F, Gasperini S, Donati M, Canessa C, Fecarotta S
Ital J Pediatr. 2022; 48(1):41.
PMID: 35248118
PMC: 8898438.
DOI: 10.1186/s13052-022-01219-4.
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M, Brand E
Drugs. 2021; 81(17):1969-1981.
PMID: 34748189
PMC: 8602155.
DOI: 10.1007/s40265-021-01621-y.
Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.
Tucker-Bartley A, Lemme J, Gomez-Morad A, Shah N, Veliu M, Birklein F
Neurosci Biobehav Rev. 2021; 124:267-290.
PMID: 33581222
PMC: 9521731.
DOI: 10.1016/j.neubiorev.2021.02.009.
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.
Jarvi N, Balu-Iyer S
BioDrugs. 2021; 35(2):125-146.
PMID: 33523413
PMC: 7848667.
DOI: 10.1007/s40259-020-00465-4.
Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.
Li C, Desai A, Gupta P, Dempsey K, Bhambhani V, Hopkin R
Genet Med. 2021; 23(5):845-855.
PMID: 33495531
PMC: 8107133.
DOI: 10.1038/s41436-020-01080-y.
Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice.
Tran J, Grover D, Zhang M, Stapels M, Brennan R, Bangari D
Clin Exp Immunol. 2020; 203(3):409-423.
PMID: 33205401
PMC: 7874831.
DOI: 10.1111/cei.13552.
Newborn Screening for Pompe Disease: Pennsylvania Experience.
Ficicioglu C, Ahrens-Nicklas R, Barch J, Cuddapah S, DiBoscio B, DiPerna J
Int J Neonatal Screen. 2020; 6(4).
PMID: 33202836
PMC: 7712483.
DOI: 10.3390/ijns6040089.
